Leadership Transition - Cerus Corporation announced the appointment of Vivek Jayaraman as President and Chief Executive Officer, effective July 1, 2026, with William "Obi" Greenman transitioning to Executive Chairman of the Board [1][2] - The leadership change is part of a succession planning process aimed at preparing for the next phase of growth at Cerus [2] Executive Background - Vivek Jayaraman has been with Cerus since 2016, initially as Chief Commercial Officer and then as Chief Operating Officer since 2020, during which he helped grow annual product revenue from less than $40 million to over $200 million by 2025 [2][3] - Obi Greenman has served as CEO for over 15 years, transforming Cerus from a pre-clinical development company into a global commercial enterprise with product sales in over 40 countries [3][4] Future Goals - Vivek Jayaraman expressed his commitment to broadening patient access to the INTERCEPT Blood System globally, expanding leadership in transfusion medicine, and improving patient outcomes [3] - Obi Greenman highlighted the company's achievements, including four FDA product approvals in the past decade and a robust innovation pipeline, positioning Cerus well for future growth [4] Company Overview - Cerus Corporation is dedicated to safeguarding the world's blood supply and aims to become the leading global blood products company, developing technologies and pathogen-protected blood components [8] - The INTERCEPT Blood System is the only pathogen reduction system with both CE mark and FDA approval for platelets and plasma, with ongoing regulatory review for the red blood cell system in Europe [8]

Investment in DraftKings - ARK added approximately 58,048 shares of DraftKings (DKNG) valued at around $1.48 million, with DraftKings holding 1.9% weightage in the ARK Blockchain & Fintech Innovation ETF and 1.05% in the ARK Next Generation Internet ETF [1] - DraftKings benefits from state-by-state legalization across the U.S., expanding its total addressable market, and is focusing on improving profitability through disciplined marketing spending and stronger customer retention metrics [1][5] - DraftKings receives a "Strong Buy" rating on Wall Street, with analysts seeing a potential upside of 45% from current levels if it hits its average price target of $36.41, and a high price target of $53 implies a potential surge of 110.7% over the next year [6] Investment in Robinhood - ARK purchased about 183,933 shares of Robinhood Markets (HOOD) worth roughly $15.12 million, with Robinhood holding 4.3% weightage in the ARK Blockchain & Fintech Innovation ETF and 4.8% in the ARK Next Generation Internet ETF [3] - Robinhood is valued at $69.4 billion and is diversifying its offerings beyond meme-stock trading, including options, retirement accounts, and credit cards [2] - Robinhood receives a "Moderate Buy" rating on Wall Street, with analysts seeing a potential upside of 63% from current levels if it hits its average price target of $125.65, and a high price target of $180 implies a potential surge of 133.5% over the next year [2] Investment in Cerus Corp. - ARK purchased 612,501 shares of Cerus Corp. (CERS) worth about $1.37 million, with Cerus holding 1.2% weightage in the ARK Genomic Revolution ETF and 0.30% in the ARK Innovation ETF [7] - Cerus specializes in pathogen reduction technology for blood safety, with its main product, the INTERCEPT Blood System, helping reduce harmful pathogens in blood components [8] - Cerus stock receives a "Moderate Buy" rating on Wall Street, with analysts seeing a potential upside of 159% from current levels if it hits its average and high price target of $5.00 [9] Investment in Compass Pathways - ARK bought roughly 100,264 shares of Compass Pathways (CMPS) valued at about $706,861, with Compass holding 1.88% in the ARK Genomic Revolution ETF [10] - Compass focuses on creating innovative mental health treatments, particularly COMP360, an investigational psilocybin-based therapy for treatment-resistant depression and PTSD [11] - Compass stock receives a "Strong Buy" rating on Wall Street, with analysts seeing a potential upside of 233% from current levels if it hits its average price target of $21.92, and a high price target of $70 implies a potential surge of 963.8% over the next year [12] Investment in Canton Strategic Holdings - ARK purchased 93,900 shares of Canton Strategic Holdings (CNTN) worth about $439,452, with Canton holding 0.19% weightage in the ARK Blockchain & Fintech Innovation ETF [13] - Canton Strategic Holdings has shifted its focus from a clinical-stage biotech company to managing a digital asset treasury centered on the Canton Network [14] - Small-cap companies like Canton can offer explosive upside if their business models scale successfully, aligning with ARK's strategy of identifying emerging disruptors [15]

Company Overview - Cerus Corporation (CERS) is a medical technology company focused on transfusion medicine and blood safety, utilizing its proprietary INTERCEPT Blood System, which includes illuminator devices and single-use processing [1] Technology and Innovation - The INTERCEPT Blood System is designed to enhance blood safety by inactivating pathogens in blood products, thereby reducing the risk of transfusion-transmitted infections [1]

Summary of Cerus Corporation Conference Call Company Overview - **Company**: Cerus Corporation - **Industry**: Medical Devices, specifically in transfusion medicine - **Mission**: To make the INTERCEPT Blood System the global standard of care in transfusion medicine, ensuring safety and availability of the blood supply [4][5] Key Points Market Position and Financial Performance - Cerus has experienced a **5x increase in sales over the last 10 years**, with current revenue guidance for the year set between **$224 million and $228 million** [6][7] - The company operates in **over 40 countries** and holds a **first-mover advantage** in the market with significant barriers to entry for competitors [7] Growth Drivers - **U.S. Market**: Approximately **60% of revenue** comes from the U.S., with a **mid-60% market share** in the platelet franchise [13][14] - **BCA Agreement**: A partnership with Blood Centers of America, representing about **50% of the U.S. market by volume**, aims to enhance penetration and adoption of INTERCEPT technology [14][24] - **International Expansion**: Germany is highlighted as a key market, with ongoing trials that could lead to significant growth in 2027 [16][46] Product Development - **INTERCEPT Fibrinogen Complex (IFC)**: Currently a U.S.-only product, with plans for international expansion. The market for IFC is expected to grow significantly as clinical appreciation increases [13][51] - **Red Blood Cells**: Anticipated approval for INTERCEPT Red Blood Cells in 2027, which could drive further growth [63][66] Market Dynamics - The **plasma market** is primarily international, with ongoing partnerships to explore adoption in Canada and other regions [29][31] - The **IFC market** is projected to grow as clinicians recognize the benefits of earlier access to fibrinogen, with a potential market size of **$300 million** in the U.S. [51][54] Challenges and Considerations - The company acknowledges the complexity of the regulatory environment and the need for ongoing clinical data to support product adoption [43][66] - Geopolitical factors, particularly in the Middle East, are monitored closely as they could impact international operations [48][46] Future Outlook - Cerus is positioned for **sustained double-digit growth** through the end of the decade, with multiple growth initiatives in place across various markets [64][66] - The company is optimistic about the potential for increased market share in the U.S. platelet market, aiming for **70%+ share** in the near term [39][38] Additional Insights - The company has a strong financial foundation, which supports its global growth strategy [7] - There is a focus on leveraging existing partnerships and expanding manufacturing capabilities to meet growing demand [61][62] - The INTERCEPT technology is seen as a unique solution that enhances blood safety, with potential applications in adjacent markets [36][57]

Financial Data and Key Metrics Changes - Total revenues for 2025 reached $233.8 million, a record level for the company, representing a 16% increase from 2024 [17] - Product revenue increased by 14% for both the fourth quarter and the full year, exceeding prior guidance of $202 million-$204 million [17][18] - Product gross margin for Q4 was 51.5%, down from 53.9% in the same period last year, impacted by higher production costs and inflationary pressures [22][23] - GAAP net loss for the full year was $15.6 million, down 25% from the prior year, indicating progress towards profitability [25] Business Line Data and Key Metrics Changes - The U.S. platelet franchise holds a market share in the mid-60s, with strong growth expected due to a new group purchasing agreement with the Blood Centers of America [11][12] - IFC product revenue grew by nearly 40% in Q4 compared to the same period last year, with a full year growth of approximately 80% [19] - EMEA product revenue increased by 25% in Q4 and 14% for the full year, driven by strong demand for platelet and plasma franchises [18] Market Data and Key Metrics Changes - The EMEA region showed robust growth, with strong double-digit growth in both platelet and plasma kit sales [13] - The INITIATE study in Germany represents a $30 million annual opportunity for platelet sales, with enrollment having commenced [14] - Demand for IFC increased by over 50% in Q4 compared to the same period last year, indicating strong market traction [15] Company Strategy and Development Direction - The company aims to establish the INTERCEPT Blood System as the global standard of care for transfused blood components, with ongoing investments in innovation and regulatory approvals [7][8] - The launch of the INT200 device is seen as a foundational element for global growth, with positive customer feedback reinforcing the company's leadership in transfusion medicine [8] - The company is focused on disciplined execution, expanding patient access, and advancing its product pipeline to deliver sustainable value [28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with solid momentum and a clear runway for continued growth, particularly in the U.S. platelet market [11] - The company anticipates continued revenue growth in 2026, reaffirming product revenue guidance of $224 million-$228 million, representing a year-over-year increase of 9%-11% [20] - Management acknowledged ongoing inflationary pressures and import tariffs as potential challenges but remains focused on maintaining operating cash flow and profitability [23][26] Other Important Information - The company ended 2025 with nearly $83 million in cash and short-term investments, indicating a strong financial position to support growth initiatives [26] - The company has seen increased inquiries from BCA member blood centers interested in initiating IFC manufacturing, reflecting positive market engagement [16] Q&A Session Summary Question: Can you elaborate on the BCA agreement and its impact? - The BCA agreement allows the company to leverage the existing supply chain and contracting platforms of BCA, which represents roughly half the U.S. blood market, facilitating broader discussions and increased INTERCEPT adoption [33][34] Question: What are the expectations for cash flow in 2026? - The company expects to continue generating operating cash flows while managing inventory to meet anticipated growth, despite previous heavy investments in working capital [36][37] Question: Can you provide an update on the INITIATE study in Germany? - The INITIATE study is expected to continue enrolling throughout 2026, with a meaningful revenue contribution anticipated in 2027 and beyond [42] Question: What is the status of red blood cells in Europe? - The regulatory submission for red blood cells has moved to ANSM, with a potential approval in the first half of 2027, depending on the review process [45] Question: What is the growth potential in the Middle East? - The Kingdom of Saudi Arabia represents a significant opportunity, with the company seeing good progress in 2025 and potential for further growth in the region [49][50]

Financial Data and Key Metrics Changes - Total revenues for 2025 reached $233.8 million, a record level for the company, representing a 16% increase from 2024 [17] - Product revenue increased by 14% for both the fourth quarter and the full year, exceeding prior guidance of $202 million-$204 million [17][18] - Product gross margin for Q4 was 51.5%, down from 53.9% in the same period last year, impacted by higher production costs and inflationary pressures [22][23] - GAAP net loss for the full year was $15.6 million, down 25% from the prior year, indicating progress towards GAAP profitability [25] Business Line Data and Key Metrics Changes - The U.S. platelet franchise holds a market share in the mid-60s, with strong growth expected due to a new group purchasing agreement with the Blood Centers of America [11][12] - IFC product revenue grew by nearly 40% in Q4 compared to the same period last year, with a full year growth of approximately 80% [19] - EMEA product revenue increased by 25% in Q4 and 14% for the full year, driven by strong demand in both platelet and plasma franchises [18] Market Data and Key Metrics Changes - The EMEA region showed robust growth, with double-digit increases in platelet and plasma kit sales [13] - The INITIATE study in Germany represents a $30 million annual opportunity, with enrollment starting in January 2026 [14][41] - Demand for IFC increased by over 50% in Q4 compared to the same period last year, indicating strong market traction [15] Company Strategy and Development Direction - The company aims to establish the INTERCEPT Blood System as the global standard of care for transfused blood components, with ongoing investments in innovation and regulatory approvals [7][8] - The launch of the INT200 device is seen as a foundational element for global growth, with positive customer feedback reinforcing the company's leadership in transfusion medicine [8] - The company is focused on disciplined execution, expanding patient access, and advancing its product pipeline to deliver sustainable value [28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with solid momentum and a clear runway for continued growth, particularly in the U.S. platelet market [11][12] - The company anticipates continued revenue growth in 2026, reaffirming product revenue guidance of $224 million-$228 million, representing a year-over-year increase of 9%-11% [20] - Management acknowledged ongoing inflationary pressures and import tariffs as potential challenges but remains focused on maintaining operating cash flow and financial stability [23][26] Other Important Information - The company ended 2025 with nearly $83 million in cash and short-term investments, indicating a strong financial position to support growth initiatives [26] - The company generated $6.2 million in operating cash flow for Q4, contributing to a full year operating cash flow of $4.8 million [26] Q&A Session Summary Question: Can you elaborate on the BCA agreement and its impact on blood centers? - Management highlighted that the BCA agreement allows leveraging existing supply chain networks and contracting platforms, which is expected to drive increased penetration in the U.S. platelet market [33][34] Question: What are the expectations for cash flow in 2026? - Management indicated that cash flow generation is expected to continue, with a focus on maintaining sufficient inventory to support anticipated growth [36][37] Question: Can you provide an update on the INITIATE study in Germany? - The INITIATE study is expected to lead to increased revenue contributions starting in 2027, with ongoing enrollment throughout 2026 [42] Question: What is the status of red blood cells in Europe? - The regulatory submission for red blood cells is currently with ANSM, with potential approval expected in the first half of 2027 [45][46] Question: What is the growth potential in the Middle East? - Management noted significant opportunities in Saudi Arabia and other countries, with strong progress observed in 2025 [49][50]

Financial Data and Key Metrics Changes - Total revenues for 2025 reached $233.8 million, a record level for the company, representing a 16% increase from 2024 [16] - Product revenue increased by 14% for both the fourth quarter and the full year, exceeding prior guidance of $202 million-$204 million [16] - Product gross margin for Q4 was 51.5%, down from 53.9% in the same period last year, impacted by higher production costs and inflationary pressures [20][21] - GAAP net loss for Q4 was $2.2 million, with a full-year loss of $15.6 million, down 25% from the prior year [24] Business Line Data and Key Metrics Changes - The U.S. platelet franchise is estimated to hold a market share in the mid-60s, with strong growth expected due to a new group purchasing agreement with the Blood Centers of America [10][11] - IFC product revenue grew by nearly 40% in Q4 compared to the same period last year, with a full-year growth of approximately 80% [18] - EMEA product revenue increased by 25% in Q4 and 14% for the full year, driven by strong demand in both platelet and plasma franchises [17] Market Data and Key Metrics Changes - The INITIATE study in Germany represents a $30 million annual platelet opportunity, with enrollment starting in January 2026 [12][41] - Demand for IFC increased by over 50% in Q4 compared to the same period last year, indicating strong market traction [13] - The company estimates that IFC market adoption exited 2025 at around 7%, with expectations to increase penetration significantly by the end of 2026 [19] Company Strategy and Development Direction - The company aims to establish the INTERCEPT Blood System as the global standard of care for transfused blood components, with ongoing investments in innovation and regulatory approvals [6][7] - The recent launch of the INT200 device is seen as a foundational element for global growth, with positive customer feedback reinforcing the company's leadership in transfusion medicine [7] - The strategic partnership with the Blood Centers of America is expected to enhance market penetration and facilitate broader discussions across the network [11][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued revenue growth into 2026, reaffirming product revenue guidance of $224 million-$228 million, representing a year-over-year increase of 9%-11% [19] - The company anticipates a third consecutive year of positive adjusted EBITDA, driven by revenue growth and disciplined expense management [25] - Management acknowledged ongoing inflationary pressures and import tariffs as potential challenges to gross margins in 2026 [21] Other Important Information - The company ended 2025 with nearly $83 million in cash and short-term investments, maintaining prudent cash management while funding growth initiatives [25] - Operating cash flow for the full year was $4.8 million, consistent with expectations despite increased investments [26] Q&A Session Summary Question: Can you elaborate on the BCA agreement and its impact on blood centers? - Management highlighted that the BCA agreement allows leveraging their supply chain and contracting platforms, which is expected to drive penetration in the U.S. platelet market [30][31] Question: What are the expectations for cash flow in 2026? - Management indicated that cash flow generation is expected to continue, with ongoing investments in inventory to support anticipated growth [34][35] Question: Can you provide an update on the INITIATE study in Germany? - The INITIATE study is expected to lead to increased revenue contributions starting in 2027, with the market opportunity estimated at $30 million annually [41][42] Question: What is the status of red blood cells in Europe? - The regulatory submission for red blood cells is under review, with potential approval expected in the first half of 2027 [44] Question: What is the growth potential in the Middle East? - Management noted significant opportunities in Saudi Arabia and other countries, with INTERCEPT platelets being influenced by U.S. standards [48][49]

Product Development and Regulatory Compliance - The INTERCEPT Blood System for platelets and plasma has received CE Certificates of Conformity and is commercialized in the U.S. and several countries in Europe, with FDA approval for the plasma system's premarket approval supplement in 2020[25]. - The red blood cell system is currently in Phase 3 clinical trials, with the RedeS study completed enrollment in 2025, but it has not yet been commercialized[25]. - The company plans to submit a PMA application for a new LED-based illuminator in mid-2026, which will require additional product development and testing[29]. - The company is required to conduct significant research and regulatory compliance activities, which may result in ongoing operating losses[21]. - The company acknowledges the need for additional safety data from commercial use to achieve broad market acceptance if certified[30]. - The company must conduct additional post-approval studies and may face significant resource expenditures, with risks that results may not align with previous studies[86]. - New PMA approvals are required for modifications to the platelet and plasma systems, and the company cannot predict the success or timing of these approvals[87]. - The company is required to obtain new PMAs for the INTERCEPT Blood System for Platelets and Plasma with a new LED-based illuminator, which may limit U.S. use to existing devices if data generation is unsuccessful[185]. - The company must notify its Notified Body of significant changes to products, which can delay the introduction of new or enhanced products[199]. - The company faces significant regulatory requirements post-market, including the need to demonstrate clinical data supporting the safety and performance of its products[211]. - Non-compliance with MDR could prevent the company from selling products in the EU, adversely affecting operations and financial projections[212]. Market Adoption and Commercialization - The company plans to shift its focus for IFC from selling finished therapeutic doses to hospitals to selling kits to blood centers, aiming to increase market adoption of INTERCEPT products[28]. - The INTERCEPT Blood System is one of the options for U.S. blood centers to comply with FDA guidance, but adoption levels remain uncertain[52]. - Coverage and reimbursement for the INTERCEPT Blood System are critical for commercialization, as the processing kits are not directly reimbursable by payors[99]. - Budgetary concerns and reimbursement structures significantly affect the adoption of the INTERCEPT Blood System in various jurisdictions[60]. - The company faces significant risks related to the commercialization of the INTERCEPT Blood System, particularly in the U.S. market, where adoption may be delayed due to administrative processes and staffing shortages[116]. - Market adoption is influenced by blood center budgets and reimbursement availability, with potential limitations from governmental and commercial payors[129]. - The current platelet shortage in the U.S. may hinder the adoption of INTERCEPT-treated platelets due to hospitals prioritizing available units over treated ones[157]. - The company is navigating a highly concentrated U.S. blood collection market, which is dominated by a small number of organizations, impacting its growth potential[121]. Clinical Trials and Research - The red blood cell system completed European Phase 3 clinical trials for acute and chronic anemia, meeting primary efficacy and safety endpoints[30]. - In the U.S., the Phase 3 RedeS study enrolled 689 patients, with preliminary results expected in late 2026 to support chronic use assessment for the red blood cell system[31]. - The ReCePI study in March 2024 demonstrated non-inferiority of INTERCEPT RBCs compared to conventional RBCs, with 581 patients enrolled across 18 clinical sites[33]. - The company completed a haemovigilance study for the platelet system, which met its endpoint and was published in a peer-reviewed journal, and has submitted recovery and survival study data to the FDA[86]. - The company has completed European Phase 3 clinical trials for both acute and chronic anemia patients, but the CE Certificate of Conformity application was closed due to insufficient data[173]. - The completion of the RedeS study and the planned final PMA module submission is anticipated in the second half of 2026, but additional clinical trial data may be required[169]. - Enrollment for the RedeS clinical trial was completed in 2025, and any delays in the PMA submission could increase development costs and delay commercialization[169]. - Clinical trials are costly and time-consuming, with uncertain outcomes that could materially affect the company's business and growth prospects[158]. Financial and Operational Risks - The company relies on BARDA agreements for funding the red blood cell system development, and any reduction or delay in funding could significantly impact revenues and cash flows[18]. - The stock price of the company is volatile, posing a risk of decline in investment value[18]. - The company anticipates significant research and development expenses to maintain compliance with regulatory requirements and pursue new PMA for platelet and plasma systems, as well as ongoing clinical work for red blood cell system[81]. - The company faces potential liability risks related to product safety, which could lead to recalls or legal claims, adversely impacting its reputation and financial results[142]. - The company’s revenue recognition under government contracts is subject to approval on audited indirect costs and may be terminated at the U.S. government's discretion[67]. - The company may incur costs related to the disposal of byproducts from IFC production if commercial outlets are not found, negatively impacting operating results[151]. - The company’s ability to supply products may be hindered by disruptions in the supply chain for compatible devices and materials, affecting customer treatment capabilities[154]. - The company’s insurance coverage may be inadequate to cover potential liabilities arising from product safety issues, which could lead to substantial financial burdens[143]. Regulatory Environment - The company is subject to diverse laws and regulations regarding data privacy and security, including the California Consumer Privacy Act and the EU General Data Protection Regulation[97]. - Compliance with the federal Anti-Kickback Statute is critical, prohibiting remuneration in exchange for referrals related to federal healthcare programs like Medicare and Medicaid[206]. - The company must adhere to the Medical Device Regulation (MDR) in the EEA, which governs various aspects of medical device regulation, including design, testing, and post-market surveillance[209]. - The company is subject to various federal, state, and foreign laws, with potential penalties for violations that could harm its reputation and financial condition[203]. - Regulatory compliance is essential, with potential consequences including fines, product recalls, and operational restrictions if violations occur[189]. - The company is subject to extensive regulations that could delay or preclude regulatory approval and market entry for its products[175]. - The potential for treatment emergent antibody reactions could lead to clinical holds and investigations, impacting the reputation and development of the red blood cell system[170]. Supply Chain and Manufacturing - The company is in the process of identifying potential alternate manufacturers for several components and reagents[44]. - The 2022 Agreement with Fresenius Kabi AG ensures the supply of disposable kits for the INTERCEPT Blood System until December 31, 2031[44]. - The manufacturing and supply agreement with Piramal has automatically renewed for two years until December 31, 2027, with minimum annual purchase requirements[49]. - The amended supply agreement with Purolite LLC has automatically renewed for an additional year, continuing to renew annually unless terminated with two years' notice[47]. - The company faces challenges with contract manufacturers, which could impact the ability to produce INTERCEPT-treated red blood cells[166]. - The company is dependent on third-party suppliers for manufacturing arrangements, which poses risks if these suppliers face issues maintaining FDA approval[121]. Competition and Market Landscape - The company faces competition from established products and companies in the pathogen reduction market, including Terumo BCT and Octapharma AG, which may impact market share[68][70][71]. - The company’s INTERCEPT Blood System is the only approved pathogen reduction product in the U.S. for platelets, subject to DOJ anti-trust oversight[71]. - The company’s ability to commercialize products in Japan may be negatively affected by Terumo's resources and existing relationships with regulators[74]. - The company must navigate competition from other pathogen reduction technologies, which may offer broader pathogen inactivation capabilities, potentially impacting market adoption of its products[149]. - The company is exploring additional configurations for its platelet system to address market needs, but this requires further product development and regulatory approvals, which may limit revenue potential[155].

Group 1: Market Overview - U.S. stock futures showed mixed results, with Dow futures declining approximately 0.1% [1] - Health insurer stocks experienced a downturn following a report about proposed unchanged rates for Medicare insurers [1] Group 2: Company-Specific Movements - Humana Inc shares fell 12.2% to $231.39 in pre-market trading due to the Medicare rate proposal [2] - Brand Engagement Network Inc saw a significant drop of 32.1% to $42.15 after a previous surge of 277% [3] - Alignment Healthcare Inc shares decreased by 11.8% to $21.00, influenced by the same Medicare rate news [3] - Propetro Holding Corp's shares fell 9.9% to $10.02 after pricing a public offering at $10 per share [3] - CVS Health Corp shares declined 9.7% to $75.73, reflecting the broader trend in health insurance stocks [3] - UnitedHealth Group Inc shares dipped 8.8% to $320.53, following the Medicare rate proposal [3] - Elevance Health Inc shares fell 7.1% to $350.01, also impacted by the Medicare news [3] - Centene Corp shares decreased by 4.7% to $44.12, in line with the trend among health insurers [3] - Sanmina Corp shares declined 8% to $168.00 after reporting disappointing earnings [3] - Cerus Corp shares fell 7.3% to $2.28 in pre-market trading [3] - Nucor Corp shares decreased by 3.1% to $172.13 due to downbeat earnings for the fourth quarter [3]

Core Viewpoint - Cerus Corporation has initiated the INITIATE study in collaboration with the German Red Cross Blood Donation Service, marking a significant step in evaluating pathogen-inactivated platelets in Germany [1] Group 1: Study Details - The INITIATE study is a prospective, multicenter, non-interventional safety study [1] - It is sponsored by the DRK Blood Donation Service Baden-Württemberg-Hessen [1] - This study is the first of its kind in Germany to assess the routine use of pathogen-inactivated platelets [1]